MONISTAT 3 COMBINATION PACK (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1996.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
MONISTAT 3 COMBINATION PACK is a topical vaginal antifungal containing miconazole nitrate, a small-molecule azole that exhibits fungicidal activity against Candida species. It is indicated for the treatment of vulvovaginal candidiasis (yeast infections) and is available as a 3-day suppository regimen in combination with external cream. The mechanism of action remains pharmacologically undefined, though animal studies confirm placental crossing at supratherapeutic doses.
Product is in late-stage lifecycle with moderate competitive pressure (30/100); brand teams should expect resource optimization and transition planning toward LOE.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 3 COMBINATION PACK at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MONISTAT 3 positions professionals in a mature, stable but declining product portfolio managed by Design Pharmaceuticals, offering limited upside but strong operational expertise in vaginal health, OTC/Rx hybrid channels, and generic competition dynamics. Career advancement will depend on driving market share defense or identifying adjacent indications rather than organic growth.